by Thomas R. Collins: There could be a role for consolidation autologous stem cell transplantation for patients with diffuse, aggressive non-Hodgkin lymphomas (NHL) who are at high risk… read more.
by Thomas R. Collins: A subgroup analysis of data from the ENDEAVOR trial, comparing carfilzomib and dexamethasone (Kd) to bortezomib and dexamethasone (Vd) — shows improved progression-free survival (PFS)… read more.
by Thomas R. Collins: Fresh off its approval in the U.S. in the relapsed/refractory setting of multiple myeloma, ixazomib continues to be examined in other patient pools, with… read more.
by Thomas R. Collins: Trials are continuing to explore potential new settings for daratumumab and elotuzumab, two monoclonal antibodies that were recently approved for use in multiple myeloma… read more.
by Thomas R. Collins: Studies on PD-1 blockade in classical Hodgkin lymphoma are still only entering Phase 2, but the early results and a history of success in… read more.
by Thomas R. Collins: Five years after the last patient’s last treatment visit, the final results are in for brentuximab vedotin’s (BV) pivotal Phase 2 study, offering perhaps… read more.
by Thomas R. Collins: Researchers have developed a prognostic “score” to gauge the chances of progression-free survival in patients with relapsed or refractory Hodgkin lymphoma who have had… read more.
by Bruce Sylvester: Anastrozole appears to be as effective as tamoxifen in treating ductal carcinoma in situ (DCIS), a very early form of breast cancer, and could offer… read more.
The majority of patients presenting with MM are elderly and pose a considerable clinical challenge in terms of disease burden and comorbidities compared with their younger counterparts. A… read more.
Gene expression profiling (GEP) is currently the best approach for defining risk in multiple myeloma (MM). Mutation detection may be used for improving risk stratification and providing additional… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
